Immunomedics inks therapy joint venture

Article

Immunomedics of Morris Plains, NJ, announced this month that it has entered into a joint venture with Beckman Coulter. The venture, IBC Pharmaceuticals, will take advantage of the two companies' compatible technologies to develop new cancer treatments.

Immunomedics of Morris Plains, NJ, announced this month that it has entered into a joint venture with Beckman Coulter. The venture, IBC Pharmaceuticals, will take advantage of the two companies' compatible technologies to develop new cancer treatments.

Immunomedics will supply its technological and marketing expertise to the venture, as well as one of its antibody patents. Fullerton, CA-based Beckman Coulter will contribute a bispecific antibody targeting technology developed by the company's Immunotech subsidiary in Marseilles, France. The technology, called the affinity enhancement system, works in a two-pronged method: A patient is first injected with the bispecific antibody that attaches to cancer cells, then is injected with a therapeutic. The process allows the tumor-killing drug to bind directly to cancer cells and kill them selectively, without affecting healthy tissue.

Immunomedics will continue its own R&D program independently of IBC, according to company chairman Dr. David Goldenberg. In addition to other diagnostic agents, Immunomedics has therapeutic agent CEA-Cide in phase I/II dose-ranging trials.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
Reducing Mammography Workload by Nearly 40 Percent? What a New Hybrid AI Study Reveals
 What New Research Reveals About Portable Low-Field MRI and Patients with Suspected Alzheimer’s Disease
Diagnostic Imaging's Weekly Scan: August 11 — August 17 (Video Version)
© 2025 MJH Life Sciences

All rights reserved.